Request for quotation – RFQZ79/5914/1 – Bioequivalence study: Empagliflozinum, 25 mg, coated tablets

In connection with the implementation of project 2022/ABM/04/00014-00 – “Development and advancement of a medicinal product with the active substance EMPAGLIFLOZIN – a generic drug for type 2 diabetes”, Tarchomińskie Zakłady Farmaceutyczne POLFA S.A. invites tenders for the subject of the contract specified below.

The project is co-financed from the state budget as part of a grant awarded by the Medical Research Agency.